Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients
Six patients with advanced cancers treated over a decade with antiparasitic drugs chosen by measuring electrical conductance at acupuncture points were reported to have lived longer than expected; the method has no established basis and the series has no controls.
Overview
Six patients with stage IV breast, lung, prostate, glioblastoma and multiple myeloma seen between 2011 and 2022 received combinations of ivermectin, mebendazole, praziquantel, niclosamide and antifungals selected by acupuncture meridian assessment, a modification of electroacupuncture according to Voll that measures skin conductance, with dental infections treated at the same time (Guilford case series 2026). The authors report survival beyond conventional expectation in all six and no serious adverse events, and call for further study (Guilford case series 2026).
- Six selected patients over eleven years; drug choice by skin-conductance readings; no controls.
A case series selected by its authors from a decade of practice cannot show that any drug worked, and the selection method has no scientific basis.
- Retrospective, uncontrolled, author-selected; several patients also had conventional treatment.
- Acupuncture meridian assessment has no validated relation to drug choice.
Similar pages
not linked directly; found by shared links- TrialAtavistic chemotherapy: combinations of antibacterial, antifungal and antiprotozoal drugs in advanced cancer (Arguello clinic, status unknown)
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
- Key paperIvermectin-benzimidazole prescribing following celebrity endorsement
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
- Key paperReal-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Mebendazole, Ivermectin, Misinformation and unproven therapies.
- Key paperIvermectin treatment for gynecologic cancers: hope versus hype
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperRETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Misinformation and unproven therapies.
- Key paperMetastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.
- Key paperIvermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperLife-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report